Business advantages
Hemofarm’s most important business advantages include: professional staff motivated towards achieving top results; technological completeness; implementation of the latest pharmaceutical standards; an extensive and up-to-date portfolio; certified quality management, as well as high quality and prestigious research and development projects.
Hemofarm group - Manufacturing Sites


Central manufacturing complex: includes four manufacturing plants (manufacture of solid pharmaceutical forms, sterile products, infusion solutions and injectables) and a high-bay warehouse - manufacture of solid dosage medicinal forms, sterile products, infusion solutions, and injectables.


Manufacture of solid, liquid and semi-liquid dosage forms.


Manufacture of antibiotics.

Banja Luka

Manufacture of solid dosage forms.


Manufacture of infusion solutions, ophthalmology products, and cephalosporin antibiotics.
Production is focused on Rx and OTC products within the most important pharmacotherapeutic groups, such as the products for treating cardiovascular diseases, antibiotics and neuropsychiatric medicines.
In 2018, Hemofarm manufactured 5.5 billion of product units, i.e. 245 million packs of finished products, which is a new company record.

All Hemofarm Group production sites have contributed to such a result, with increasing production for the demanding EU markets, while representing the major manufacturer and the backbone for further development at the level of STADA Group.
Sales in EU
The production of a considerable number of products for STADA Group intended for sale in EU countries is the acknowledgement of the modern concept of pharmaceutical industry, top-notch technological equipment and staff competence.

With the manufacturing capacity of 46 million bottles per annum, Hemofarm is among five largest European manufacturers of infusion solutions.